ArticleEClinicalMedicine2026
Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic survival prediction using longitudinal AGR in unresectable locally advanced esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal fractionation patterns and safety of hypofractionated radiotherapy remain poorly defined in locally advanced oesophageal squamous cell carcinoma (LA-ESCC). We aimed to determine the maximum tolerated fraction dose (MTFD) of split-course concurrent chemoradiotherapy (CCRT) following induction chemo-immunotherapy in patients with LA-ESCC. Methods: In this phase 1 study, patients (aged 18-80 years) with unresectable, histologically confirmed LA-ESCC (stage T1-4, N0-3, M0-1 disease; ECOG 0-1) were enrolled from one site in China (Sun yat-sen University Cancer Center, Guangzhou, Guangdong). Eligible participants had no prior treatment with chemotherapy, radiotherapy, surgery, or immunotherapy for ESCC and no evidence of deep ulceration on baseline esophagoscopy. Enrolled participants received two cycles of induction albumin-bound paclitaxel (260 mg/m Findings: Between Aug 31, 2023, and July 23, 2024, 18 patients were enrolled (n = 6 per dose), and all completed split-course CCRT per protocol. The MTFD was not reached, and dose level 3 was tolerable. The most common grade 3 toxicity was lymphopenia (72.2%), followed by esophagitis (11.1%). No grade 4 or 5 toxicities occurred. The objective response rate after induction therapy was 100%. After CCRT, the clinical complete response rate was 83.3%. With a median follow-up of 20.5 months, median progression-free and overall survival were not reached; 1-year rates were 88.9% and 94.4%, respectively. Interpretation: Fraction dose-escalated split-course CCRT following induction chemo-immunotherapy was feasible, well tolerated, and showed encouraging preliminary efficacy. Larger prospective studies are warranted. Funding: The National Key Research and Development Program of China and the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.